Higher-Dose Wegovy 7.2 mg (Semaglutide 7.2 mg Once Weekly Subcutaneous Injection, Up From the Current 2.4 mg Maximum Approved Dose) Is Under FDA Review for the Adult Obesity Indication Based on Phase 3 STEP UP Trial Data That Documented Approximately 19% Weight Loss at the 7.2 mg Dose Versus Approximately 15% for the Current 2.4 mg Dose, Providing Novo Nordisk With a Higher-Efficacy Line-Extension Option Even as the Lilly Tirzepatide Franchise (Zepbound, Mounjaro) Continues to Outperform on Weight Loss (Approximately 21% for 15 mg Weekly) and Lilly's Retatrutide Triple-Agonist Phase 3 Data Has Documented 28.7% Weight Loss at the 12 mg Dose in TRIUMPH-4
The higher-dose Wegovy 7.2 mg (semaglutide 7.2 mg once weekly subcutaneous injection, up from the current 2.4 mg maximum approved dose) is currently under FDA review for the adult obesity indication. The submission is based on the Phase 3 STEP UP trial that documented approximately 19% weight loss at the 7.2 mg dose over 68 weeks, versus approximately 15% weight loss for the currently-approved 2.4 mg dose (based on STEP 1 registrational data). The higher-dose submission provides Novo Nordisk with a line-extension option to defend the Wegovy franchise economics against the Eli Lilly tirzepatide franchise (Zepbound and Mounjaro), which continues to outperform on weight loss (approximately 21% at the 15 mg weekly dose per SURMOUNT-1). The Wegovy 7.2 mg efficacy also lags the Lilly retatrutide triple-agonist Phase 3 TRIUMPH-4 data that documented 28.7% mean body weight reduction at the 12 mg dose (the highest weight-loss magnitude in any Phase 3 obesity trial to date). Novo Nordisk's line-extension strategy is under scrutiny following the CagriSema REDEFINE 4 head-to-head miss versus tirzepatide (23.0% vs 25.5% treatment-policy estimand at 84 weeks). FDA decision timing on Wegovy 7.2 mg has not been publicly disclosed.